Over 200 million people suffer from osteoporosis worldwide, one third of which will develop osteoporotic bone fractures. Unfortunately, no effective cure exists. Mutations in plastin 3 (PLS3), an F-actin binding and bundling protein, cause X-linked primary osteoporosis in men and predisposition to osteoporosis in postmenopausal women. Moreover, the strongest association so far for osteoporosis in elderly women after menopause was connected to a rare SNP in PLS3, indicating a possible role of PLS3 in complex osteoporosis as well. Interestingly, 5% of the general population are overexpressing PLS3, with yet unknown consequences. Here, we studied ubiquitous Pls3 knockout and PLS3 overexpression in mice and demonstrate that both conditions influence bone remodeling and structure: while Pls3 knockout mice exhibit osteoporosis, PLS3 overexpressing mice show thickening of cortical bone and increased bone strength. We show that unbalanced PLS3 levels affect osteoclast development and function, by misregulating the NFκB pathway. We found upregulation of RELA (NFκB subunit p65) in PLS3 overexpressing mice-known to stimulate osteoclastogenesis-but strikingly reduced osteoclast resorption. We identify NFκB repressing factor (NKRF) as a novel PLS3 interactor, which increasingly translocates to the nucleus when PLS3 is overexpressed. We show that NKRF binds to the NFκB downstream target and master regulator of osteoclastogenesis nuclear factor of activated T cells 1 (Nfatc1), thereby reducing its transcription and suppressing osteoclast function. We found the opposite in Pls3 knockout osteoclasts, where decreased nuclear NKRF augmented Nfatc1 transcription, causing osteoporosis. Regulation of osteoclastogenesis and bone remodeling via the PLS3-NKRF-NFκB-NFATC1 axis unveils a novel possibility to counteract osteoporosis.
Introduction
Bone disorders are very common and can affect every individual, regardless of sex, race or age, equally. Impaired life quality as well as rising costs of treatment become increasingly important socioeconomic issues (1, 2) . Consequently, searching for an understanding of the underlying processes causing skeletal pathologies is essential to identify novel targets for disease prevention.
Structural integrity of bone is generally controlled through bone remodeling, relying on the equilibrium between bone formation and resorption. This dynamic process depends on three major cell types: bone forming osteoblasts, mechanosensory osteocytes and bone degrading osteoclasts (3) (4) (5) . Misbalancing causes skeletal disorders ranging from severe bone loss to increased bone mass. Interestingly, genetic predisposition for osteoporosis is relevant in 60-80% of patients (6) .
Plastin 3 (PLS3) mutations cause X-linked primary osteoporosis and osteoporotic fractures in men and mild osteoporosis in women (7) (8) (9) (10) (11) (12) (13) . The majority of these mutations induces mRNA degradation and thereby PLS3 depletion. Strikingly, a rare variant in PLS3 shows the strongest association for osteoporosis in elderly women after menopause so far, implying that also complex osteoporosis is influenced by PLS3 (7) . PLS3 is an F-actin binding and bundling protein present in all solid tissues and cell types essential for bone remodeling, except blood (14) (15) (16) (17) . Although , not yet understood, about 5% of the general population overexpress PLS3 in blood as well as in motor neurons differentiated from IPSC derived from fibroblasts of the same PLS3 overexpressing (OE) individuals. Moreover, PLS3 overexpression acts as a female-specific protective modifier of spinal muscular atrophy (SMA) (15, 18) . PLS3 is localized in dendritic processes of osteocytes, suggesting an involvement in mechanosensitivity (7, 19) . Likewise, osteoblastic mineralization was proposed to be affected by PLS3 (8) . PLS3 is also present in podosomes of osteoclasts and was functionally linked to cortactin during sealing ring formation (17, 20) . Additionally, PLS3 mutations were found to influence bone resorption in patients, further reinforcing an osteoclast-related function (9) . The precise function of PLS3 in bone is still unknown; however, these findings propose PLS3 as a new crucial regulatory protein in bone homeostasis.
To unravel the role of PLS3 in bone, we made use of a ubiquitous Pls3 knockout (KO) as well as PLS3 OE mouse model. We provide evidence of a PLS3-dependent alteration of bone microstructure and strength resulting in either osteoporosis or thickening of cortical bone and increased bone strength. Moreover, we demonstrate that PLS3 is an essential regulator of osteoclastogenesis through interaction with the NFκB repressing factor (NKRF) thereby altering NFκB-induced mRNA expression of the crucial transcription factor nuclear factor of activated T cells 1 (Nfatc1). Additionally, we show that PLS3 dysregulation results in altered resorptive activity, likely connected to impaired podosome organization. Altogether, our results revealed PLS3 as a promising therapeutic target for bone-related diseases.
Results

PLS3 modulates bone microarchitecture and strength
To unveil the PLS3 function in bone development and maintenance, we used our earlier generated conditional PLS3 OE transgenic mice (21) and purchased a conditional Pls3 KO mouse line (EMMA-ID: EM:06997, Sanger). By crossing these mouse models with the cytomegalovirus (CMV)-Cre-deleter mice, PLS3 was either ubiquitously OE or KO including the germ cells, so that progenitors exhibit a permanent Pls3 KO or PLS3 OE in all cells. The V5-PLS3 transgene has been recombined into the Rosa26 locus on chromosome 6 (21) . All animals used in this work are homozygous for the V5-PLS3 transgenic allele. In contrast, the endogenous Pls3 is localized on the X chromosome, and therefore males are hemizygous (Pls3 KO ) whereas females used for analysis are homozygous for the Pls3 knockout allele (Pls3 KO/KO ).
To verify ubiquitous Pls3 KO, we extracted proteins from spinal cord, quadriceps and liver of 3-month-old (3M) mice (Supplementary Material, Fig. 1 ). Ubiquitous expression of transgenic PLS3 OE has been validated (21, 22) . Both conditions were subsequently also confirmed in cultured osteoclasts (see later results).
Initially, micro-computed tomography (μCT) analysis of wild type (WT), Pls3 KO and PLS3 OE femora was assessed separately in 3M-old male and female mice and compared to the same sex of WT mice, to unveil sex-specific differences ( Fig. 1A-P) . Threedimensional reconstruction of representative data revealed a visible osteoporotic phenotype in cortical and trabecular bone structure of Pls3 KO animals, with a more prominent phenotype in males (Fig. 1A) . However, both sexes showed severely reduced trabecular number (Tb.N), with a corresponding increase of trabecular separation (Tb.Sp), a significant decrease in cortical thickness (Ct.Th), cortical area (Ct.Area) and cortical area to tissue area ratio (Ct.Ar/Tt.Ar). Trabecular thickness (Tb.Th) was unaffected in either male or female Pls3 KO mice (Fig. 1C-H) . Instead, bone volume (BV/TV) was decreased only in Pls3 KO females but not in males (Fig. 1B) .
In contrast, PLS3 OE revealed a noticeable thickening of cortical bone but a reduced number of trabecular bone (Fig. 1I) . Thus, PLS3 OE caused a decrease in Tb.N and an increase in Tb.Sp in both sexes. Ct.Th and Ct.Ar/Tt.Ar were significantly increased in female mice but unaffected in males. BV/TV as well as Tb.Th and Ct.Ar revealed no significant difference in either sex compared to WT ( Fig. 1J-P) .
Next, we evaluated the PLS3 influence on bone strength, by applying a 3-point-bending-test (3PBT) (Supplementary Material, Fig. 2A and B) . Pls3 KO males showed a significant decrease of breaking force, ultimate stress and stiffness compared to WT males. Female Pls3 KO animals were mildly affected, depicting a reduction in ultimate stress only (Supplementary Material, Fig. 2A ). In contrast, PLS3 OE female mice exhibited increased breaking force, stiffness and E-modulus, whereas male mice did not differ from WT animals (Supplementary Material, Fig. 2B ).
Hence, these results demonstrate a marked effect of PLS3 on bone microarchitecture and strength resulting in either osteoporosis, in Pls3 KO mice-resembling the human phenotype-or thickening of cortical bone parameters and an increased bone strength in female PLS3 OE mice.
Osteoclast activity and podosome structure is modified by PLS3
Since Pls3 KO and PLS3 OE revealed no differences in early bone mineralization, spatial organization or longitudinal column alignment of chondrocytes in growth plates of 5-day-old (P5) mice (Supplementary Material, Fig. 3 ), we next suspected an impairment in osteoclast function.
Increased bone density, as observed in cortical bone of female PLS3 OE mice, might develop through insufficient function or decreased number of osteoclasts (23) . Contrarily, osteoporotic bone loss, as seen in Pls3 KO animals, might be linked to increased resorptive activity of osteoclasts (24) . Therefore, staining of the osteoclast marker tartrate-resistant-alkalinephosphatase (TRAP) was performed on femora of postnatal day 5 (P5) and 3M-old animals. Interestingly, osteoclast numbers were reduced in PLS3 OE mice at P5 but not at 3M, whereas Pls3 KO osteoclasts were unaltered at both time points ( Fig. 2A,  Supplementary Material, Fig. 4) .
Next, osteoclast function was analyzed in PLS3 OE and Pls3 KO animals. Therefore, bone marrow from 3M-old mice was isolated and differentiated into osteoclast cultures. Successful differentiation was verified by TRAP staining of cell cultures (Supplementary Material, Fig. 5A ). Additionally, expression of transgenic PLS3 or lack of protein in Pls3 KO was confirmed by Western blot, respectively. The level of PLS3-V5 relative to endogenous PLS3 in PLS3 OE mice was quantified and revealed similar increase of 3.7-fold in female and 3.5-fold in male animals (Supplementary Material, Fig. 5B ). Osteoclast size did not show any significant difference (Supplementary Material, Fig. 5C ), nor the number of nuclei per osteoclast was altered in both Pls3 KO or PLS3 OE osteoclasts (Supplementary Material, Fig. 5D ).
To determine resorptive activity, osteoclasts were predifferentiated, afterwards plated on bovine bone slices and the resorbed area was quantified after 7 days. Pls3 KO osteoclasts revealed a notably increased resorption compared to WT, while it was markedly decreased in PLS3 OE (Fig. 2B) .
Resorptive activity, migration and adhesion of osteoclasts are highly dependent on formation of large actin-filament containing ring structures known as podosomes (25) . Consequently, to understand the PLS3-mediated change in resorptive activity, staining of podosome marker cortactin was performed in Pls3 KO and PLS3 OE osteoclasts. First, the presence or absence of podosome structures was determined. Subsequently, present podosomes were categorized according to their 'ring' or 'dot/cluster-like' morphology (Fig. 2C) . Pls3 KO osteoclasts showed no difference in podosome presence or absence compared to WT. However, there was substantially more podosome cluster than ring formation in Pls3 KO. Remarkably, PLS3 OE osteoclasts presented in more than half of the cells no podosome structures at all, but demonstrated a shift towards podosome cluster assembly in the remaining other half.
These results indicate that PLS3 levels in osteoclasts influence podosome formation and shape, possibly impacting resorptive activity. Subsequently, disturbed osteoclastmediated resorption results in either osteoporosis in Pls3 KO or in the observed morphological changes in femora of PLS3 OE mice. 3M-old mice grown on bovine bone slices for 7 days. N = 3, n > 50 resorption pits. Scale bar = 50 μm. (C) Cortactin staining in Pls3 KO and PLS3 OE compared to WT osteoclasts of 3M-old mice. Quantification approach consisted in first identifying present or absent podosomes and second, podosome morphology as cluster or ring shaped. Cortactin = green, Phalloidin = red, Hoechst = blue. Scale bar = 20 μm. N = 3, n > 100 osteoclasts. All results are shown as mean ± SEM. * P < 0.05, * * P < 0.01, * * * P < 0.001, n.s. = not significant. Statistical test: unpaired two-tailed t-test.
RELA is increased in PLS3 OE osteoclast cultures
Both Pls3 KO and PLS3 OE osteoclasts demonstrated severe defects in podosome formation, which is known to be highly dependent on a functional NFκB pathway. For instance, inhibition of the canonical NFκB pathway prevents osteoclastogenesis and consequently resorptive activity (26) . Accordingly, to answer whether PLS3 alterations influence the NFκB pathway, we analyzed protein levels of essential NFκB pathway players. Surprisingly, V-REL avian reticuloendotheliosis viral oncogene homologue A (RELA; NFκB subunit p65) was significantly upregulated in PLS3 OE osteoclasts compared to WT but not changed in Pls3 KO osteoclasts ( Fig. 3A and B) . However, phosphorylation of RELA on serine 536 was significantly reduced in PLS3 OE. Previous studies reported that phosphorylation at this specific site is essential for nuclear translocation of RELA without affecting its transcriptional activity, thus indicating decreased nuclear transport of RELA in PLS3 OE osteoclasts (27) . No significant changes were found for inhibitor of nuclear factor kappa B kinase (IKK), NFκB inhibitor alpha (IκBα) or phosphorylated (p)-IκBα in either PLS3 OE or KO ( Fig. 3A and B) . Moreover, increased RELA in PLS3 OE was additionally confirmed by immunostainings (Fig. 3C) . No upregulation was observed in other tissues (lung, liver and heart), suggesting a rather bonespecific PLS3-mediated effect (Supplementary Material, Fig. 6 ).
To corroborate if RELA increase underlies transcriptional variations or cellular accumulation, semi-quantitative real-time polymerase chain reaction (PCR) was performed in osteoclasts. In both models, no significant difference versus WT was observed for Rela (Fig. 3D) . Thus, we hypothesized that RELA upregulation in PLS3 OE is rather due to translational than transcriptional changes. Rela expression in osteoclasts of 3M-old Pls3 KO and PLS3 OE mice. Hprt was used as housekeeping gene for normalization. N = 3. All results are shown as mean ± SEM. * P < 0.05, * * P < 0.01, * * * P < 0.001, n.s. = not significant. Statistical test: unpaired two-tailed t-test.
PLS3 influences NFκB signaling through nuclear translocation of NKRF
The unexpected increase of RELA protein but its decreased phosphorylation in PLS3 OE pointed towards an indirect PLS3-dependent role in modifying the NFκB pathway. Remarkably, Pls3 KO did not show any variation in RELA protein levels (Fig. 3B ). Since we clearly confirmed altered resorption and podosome formation in both Pls3 KO and PLS3 OE osteoclasts, we hypothesized that other players involved in the NFκB pathway might play a mediating key role. Our previously performed mass spectrometry analysis using a stably expressing V5-tagged PLS3 HEK293T cell line unveiled NKRF as a putative interacting partner of PLS3 (28) . This interaction was confirmed by an independent co-immunoprecipitation (Co-IP) experiment in HEK293T cells transfected with NKRF-Myc/DDK expression vector. As shown by using western blot analysis, endogenous PLS3 protein was co-immunoprecipitated (Fig. 4A ). The reverse Co-IP using PLS3 antibodies failed, most likely due to a too weak interaction and the binding of PLS3 to actin, later binding a large number of proteins, impeding the already weak interaction between PLS3 and NKRF.
NKRF is a transcriptional repressor which either inhibits NFκB activity through direct protein-protein interaction in vitro (29) or by blocking specific negative regulatory elements (NREs) in the nucleus (30) . Thus, to evaluate if PLS3 influences NKRF localization, we analyzed NKRF abundance in PLS3 OE and Pls3 KO osteoclasts. Remarkably, NKRF was highly increased in the nuclei of PLS3 OE osteoclasts. In contrast Pls3 KO nuclei were almost devoided of NKRF (Fig. 4B) , indicating a PLS3-dependent nuclear translocation. Importantly, PLS3 was significantly more abundant in the nuclei of PLS3 OE compared to WT osteoclasts as well (Supplementary Material, Fig. 7) , suggesting a putative direct involvement of PLS3 in translocation of NKRF to the nucleus.
Hence, our results suggest that PLS3 might modify transcriptional regulation of NFκB downstream targets through a shift in NKRF nuclear translocation. If this assumption is correct, the expression of essential NFκB downstream targets should be altered as well.
To conclusively prove this hypothesis, we quantified transcription levels of direct NFκB targets, namely, master regulator of osteoclastogenesis Nfatc1 (31) and IκBα (32) . Transcription of these genes is induced upon binding of receptor activator of NFκB ligand (RANK-L) to its receptor RANK subsequently initiating the NFκB pathway in osteoclasts (33) . Notably, Nfatc1 was significantly upregulated in Pls3 KO and downregulated in PLS3 OE osteoclasts (Fig. 4C) . IκBα levels were unaffected in both genotypes; however, a non-significant decrease was observed in PLS3 OE (Fig. 4D) . Furthermore, we analyzed protein levels of NFATC1 to evaluate if transcriptional changes impact translation as well ( Fig. 4E and F) . Cohesively, NFATC1 was slightly upregulated in Pls3 KO and significantly downregulated in PLS3 OE. Additionally, cathepsin K (CTSK) levels, a key protein involved in resorption, were checked but did not show any difference in PLS3 OE or Pls3 KO compared to WT (Fig. 4E and F) . However, it was demonstrated that Nfatc1 deficiency causes osteopetrosis in mice (34) ; thus, we suggest that PLS3-dependent changes of Nfatc1 transcription might explain the observed skeletal phenotypes.
Since Nfatc1 expression was affected in Pls3 KO and PLS3 OE mice, we hypothesized that NKRF might directly inhibit Nfatc1 transcription upon binding to its promotor region. Thus, chromatin immunoprecipitation (ChIP) was performed in WT osteoclasts using interferon beta (Ifn-β), which was shown to be negatively regulated by NKRF and therefore used as positive control, to check the binding capacity of NKRF to the NRE of Nfatc1 (Fig. 4G) (29) . No difference was observed between NKRF binding to Ifn-β or Nfatc1, indicating direct binding of NKRF to Nfatc1. Thus, our data suggest that PLS3-mediated relocation of NKRF might be causative for the transcriptional changes observed for Nfatc1 in both Pls3 KO and PLS3 OE osteoclasts, consequently being responsible for the observed bone phenotypes.
Taken together, here we propose a novel and crucial PLS3-dependent regulatory pathway in osteoclasts affecting NFκB signaling and downstream targeting of crucial osteoclastogenic factors (Fig. 5) . We hypothesize that NKRF localization to the nucleus is decreased in Pls3 KO, thereby influencing NFκB-mediated transcriptional activation of the master regulator Nfatc1. Correspondingly, NKRF translocation to the nucleus in PLS3 OE is enhanced, presumably inducing transcriptional inhibition of Nfatc1 and accumulation of RELA in the cell.
Discussion
Mutations in PLS3 were reported to cause X-linked primary osteoporosis in males and a variable bone phenotype in females (7). Previous studies hypothesized a possible role of PLS3 in mechanosensoring of osteocytes or in bone mineralization. Additionally, an increase in osteoclast surface was found in two male patients, indicating putative osteoclast-mediated defects (7-9). However, the exact function of PLS3 in bone homeostasis remained elusive.
In this study, we made use of a ubiquitous Pls3 KO and PLS3 OE mouse model to elucidate how PLS3 affects bone homeostasis and to unravel the underlying pathomechanism. We show that Pls3 KO male and female mice both develop an osteoporotic phenotype, with male mice being more severely affected, resembling the human phenotype. PLS3 OE mice reveal a significant increase of Ct.Th in females and a decrease of Tb.N in both sexes. These results clearly show a sex-specific dependency of the bone phenotype in both Pls3 KO and PLS3 OE animals. Endogenous human PLS3 as well as murine Pls3 are located on the X-chromosome (35) . Interestingly, PLS3 was proposed to undergo X-inactivation, suggesting that the variations in the bone phenotype between male and female mice might be due to PLS3 escaping gene inactivation (36) . Indeed, it has been demonstrated that X-linked escape genes are related to sex-specific phenotypic alterations in various diseases and that the predisposition for disease development is highly sex-related (37) (38) (39) . Hence, we hypothesize that Pls3 might escape X-inactivation thereby causing the sex differences in Pls3 KO animals. Contrarily, the PLS3V5 transgene in PLS3 OE mice is located on chromosome 6, thus other factors might contribute to the sex specificity in these mice.
Next, we reveal altered resorptive activity and podosome formation in both mouse models, indicating an osteoclast-specific dysregulation probably causing the observed bone phenotypes. Moreover, early mineralization or chondrocyte development and spatial organization was not altered in either Pls3 KO or PLS3 OE mice. Nevertheless, it is well known that regulation of osteoclastogenesis as well as osteoclast function is coupled to local intracellular communication with osteoblasts through RANK-L and macrophage colony stimulating factor 1 secretion and subsequent initiation of formation of mature osteoclasts (40) . Previous studies have confirmed that an increase of bone resorption by pharmacological agents was coupled to an increase in bone formation as well (41) . Contrarily, deficiency of bone resorption in osteoporotic mouse models was shown to result in rather decreased or unaltered bone formation (42, 43) . This study mainly focuses on PLS3-dependent alterations of osteoclast function and the underlying mechanisms in ubiquitous mouse models, showing altered resorptive activity and changes of the NFκB pathway. However, it cannot be excluded that osteoblast formation or activity is not affected as well consequently contributing to the PLS3-dependent alterations in bone homeostasis.
Furthermore, podosome formation is crucial for proper bone resorption. Actin bundling and binding proteins, including PLS3, were proposed to play a major role in podosome assembly (44, 45) . F-actin turnover during podosome formation undergoes fast assembly and disassembly, which is highly dependent on the presence and functionality of several cytoskeletal associated proteins (46) . Gelsolin depletion in mice, for instance, was shown to result in mild osteoporosis (47) . Remarkably, Pls3 KO and PLS3 OE osteoclasts both portrayed difficulties in podosome ring All results are shown as mean ± SEM. * P < 0.05, * * P < 0.01, * * * P < 0.001, n.s. = not significant. Statistical test: unpaired two-tailed t-test, for ChIP analysis Holm-Bonferroni correction was applied for multiple comparisons. formation compared to WT (Fig. 2C) . Overexpression of PLS3 in SMA patients was demonstrated to restore F-actin levels thereby stabilizing the actin cytoskeleton and rescuing the pathogenic phenotype (15) . Although in this disease context the effect was beneficial, altering PLS3 levels in either direction might be detrimental for podosome assembly in osteoclasts. Keeping the assembly and disassembly of actin filaments in an equilibrium is essential for this error-prone process. Hence, overexpression of PLS3 could potentially lead to reduced F-actin disassembly, provoking augmented stiffness of the actin cytoskeleton, thereby blocking podosome formation to a great extent. In contrast, loss of PLS3 might weaken cytoskeletal stability by amplifying disassembly of F-actin. Accordingly, podosome clusters might be prevented from further assembly into full podosome rings.
Furthermore, podosome formation is highly dependent on fast actin filament turnover with a completely renewal of all Factin polymers in a single podosome of clusters every 20-60 s during the average lifespan of around 3 min (46) . The lifespan of individual podosomes in ring structures has been shown to be a lot shorter, being around 1 min (48). Thus, an involvement of PLS3 in the lifespan of podosome clusters might be plausible. Hypothetically, actin filament turnover might be faster in Pls3 KO osteoclasts due to cytoskeletal destabilization, thereby decreasing the lifespan of individual podosomes. Hence, it could be possible that the here shown increased number of podosome clusters is based on the fact that the lifespan of podosome rings is shortened but not completely abolished. Additionally, this might explain the fact that Pls3 KO osteoclasts are still able to actively perform bone resorption. Still, how PLS3 exactly affects podosome formation needs further studies.
It should be noted that PLS3 was proposed to have a major role in intracellular trafficking since overexpression was reported to increase fluid phase endocytosis (22) . Additionally, PLS3 was proven to interact with endosomal marker Rasassociated protein 5 (RAB5), further supporting this finding (22, 49) . Endocytosis of degraded material, exocytosis and intracellular vesicular trafficking are essential for proper osteoclast function and dynamic membrane turnover (50, 51) . Indeed, several studies showed that dysregulation of RAB proteins or GTPases impairs vesicular trafficking causing deficiencies in osteoclast function (52, 53) . Moreover, functional actin cytoskeleton dynamics were shown to be essential for transcytosis since cytochalasin treatment was causing significantly slower vesicular trafficking through F-actin disruption (54) . Hence, Pls3 KO and PLS3 OE might have a distinct effect on vesicular trafficking in osteoclasts, possibly contributing to the observed changes in bone morphology.
Finally, ubiquitous Pls3 KO results solely in osteoporosis in mice as well as humans without any additional pathological phenotype observed so far. It was shown though, that high doses of pls3 morpholino, resulting in almost complete absence of pls3, were lethal in zebrafish embryos, while lower doses were tolerated (15) . These results suggest that complete absence of PLS3 protein should probably cause a much broader pathological phenotype. Hence, other actin bundling proteins might compensate for PLS3 loss in other tissues and organs of mice and humans, protecting them from a more severe phenotype. Further studies on the modifying function of other possible key players involved may provide important insights into PLS3 function.
Taken together, PLS3 is a novel regulator of bone homeostasis and its implication in the NFκB pathway offers novel insights in understanding pathologies in NFκB-dependent diseases. However, future work, based on cell type-specific Pls3 KO or PLS3 OE, is required and may enhance our knowledge to whether impaired osteoclast function is sufficient to cause PLS3-related osteoporosis or additional factors are required.
Materials and Methods
PLS3 OE mouse model
The PLS3V5 transgenic mouse model was generated previously in our lab (21) . Briefly, human PLS3-V5-tagged cDNA was expressed under the CMV enhancer/chicken β-actin promotor with a transcription stop cassette flanked by loxP sites localized between the promotor and the PLS3V5 cDNA. Removal of the stop cassette allows conditional or ubiquitous activation of PLS3V5 transgene. This construct has been recombined into the Rosa26 locus, on chromosome 6. PLS3V5-floxed lines were generated to ubiquitously KO the stop cassette and were crossbred with the ubiquitously Cre-expressing line CMV-Cre (55) . Once the stopcassette was genomically deleted via Cre in the germline and this was inherited to the next generation, the Cre allele was no longer necessary to ubiquitously activate PLS3V5. These mice were defined as PLS3V5 tg/wt . The offspring was backcrossed for seven generations against congenic C57BL/6N mice to achieve genetic purity. Genotyping for these mice was performed using the following primers and PCR setup: (EMMA-ID: EM:06997, Welcome Trust Sanger Institute) mouse line was bought to achieve ubiquitous Pls3 KO animals. Breedings, primers, allele names and PCR conditions were applied as suggested by the manufacturer. In brief, mice were imported into the mouse facility through embryo transfer. First, preconditional mice containing the complete selection cassette (cassette not removed: tm1a) had to be bred with FLP-deleter mice (56) to obtain the conditional flipped out mutant allele (cassette removed: tm1c). Genotyping for these mice was performed using the following primers and PCR setup: primer setup for the expressing the tm1c allele were bred with a CMV-Cre-deleter line (55) to obtain excision of exon 2 of the Pls3 gene (tm1d). Genotyping for these mice was performed using the following primers and PCR setup: primer setup for the tm1d allele: Tm1c F: AAG GCG CAT AAC GAT ACC AC; Floxed LR: ACT GAT GGC GAG CTC AGA CC. The expected amplicon size was 174 bp if exon 2 was removed. If Cre recombination failed amplicon size was around 1.5 kb. PCR settings were the same as used before. In addition to these allele-specific primer conditions, genotyping of either WT or mutant cassette was performed in all cases to check for homo-or heterozygosity in case of females or hemizygosity in case of males. The following primer setup was used: Pls3 F: TAC GCC ATT ACT CCC CAT CC; Pls3 R: TTT CAC ACA CTC GCC AAA CAC, CAS R: TCG TGG TAT CGT TAT GCG CC. The expected amplicon size was 581 bp for the WT allele and 311 bp for the mutant cassette. PCR settings were applied as described before. All mice were held on a congenic C57BL/6N background. Congenic wildtype C57BL/6N mice were used as controls. Animals were kept under a 12:12 h light/dark cycle with constant access to food and water.
Experimental design and ethical approval
Prior to analysis, all experiments were blinded for the experimenter by an independent person as suggested by the ARRIVE guidelines. All experiments were performed at least in triplicates, and statistical analysis was performed by using the mean value of each animal per experiment to avoid pseudoreplication. In all experimental procedures, 3M-old female mice were used if not stated otherwise. Based on the fact that the average age of patients affected by osteoporosis due to PLS3 mutations is early adulthood, mature adult mice were chosen to be analyzed in this study. Previous studies showed that 3-6M-old mice are equivalent to the age of 20-30 years in humans (57) . All experimental procedures were approved by the Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen (4.17.003 and 84-02.04.2014.A406).
μCT μCT was used for nondestructive three-dimensional evaluation of trabecular bone in the metaphysis and cortical bone in the diaphysis as previously described (58) . Briefly, femora were scanned in 0.9% NaCl including protease inhibitors (Sigma Aldrich, Steinheim, Germany) at a voxel size of 7 × 7 × 7 μm, 70-kVp tube voltage, 114-mA tube current and 400-ms integration time using a Scanco μCT35 scanner (Scanco Medical AG, Bassersdorf, Switzerland). A constrained Gaussian filter (trabecular bone: support = 1, sigma = 0.8; cortical bone: support = 2, sigma = 0.8) was used to remove noise in the original volume data. In order to extract the trabecular bone, data were globally thresholded with 20% for the female and 25% for the male animals. For the cortical bone, a threshold of 29.5% for all the animals was applied. 143 slices (1 mm) were evaluated in the distal femur with the volume of interest 1 mm below the growth plate which included only secondary spongiosa. 
3PBT
Mechanical properties of femora were analyzed using an electromechanical testing machine (Z2.5/TN1S; Zwick; Germany) as previously described (59) . Briefly, femora were loaded at mid-diaphysis in anterior-posterior direction using a 100-N load cell. The distance between support points, 1.5 mm in diameter, was 5 mm. After preloading at 0.1 N, 0.05 mm/s, a loading rate of 1 mm/min was applied perpendicularly to the long axis of the bones. Ultimate load (N), deformation (mm), stiffness (N/mm) and energy (mJ) were measured from the loaddeformation curve. Ultimate stress (MPa) and ultimate strain (%), E-Modulus (MPa) as well as energy density (mJ/mm 3 ) were calculated based on the area moments of inertia obtained from pQCT measurements.
Femoral extraction and preparation
Preparation of murine femora and isolation of bone marrow for cell culture was performed as previously described (60) . Briefly, mice were sacrificed and an incision was made above the hip joint to remove the skin and expose muscle tissue. To remove the hind leg, muscle tissue was removed until the hip joint was exposed. Afterwards, the femur was isolated from the hip by carefully dislocating the femur at its proximal end upwards. The tibia was removed by cutting through the ligaments beneath the femur. Femora were placed in HBSS for 5-10 min to loosen remaining tissue and were afterwards carefully cleaned from all tissue and placed in 70% EtOH for disinfection until further procedures.
Osteoclast differentiation
Isolation of bone marrow from femora was performed as previously described (48) .
Briefly, ends of femora were trimmed and bone marrow was flushed out using a 1-ml, 29G 1 / 2 syringe. Supernatant was washed two times by two times centrifugation and in-between medium changes. The cell pellet was resuspended in 10-ml RPMI-1640 + 10% FKS, + Pen/Strep. Differentiation was obtained by addition of 400-ng/ml M-CSF for 3 days and subsequent growth of cells for two times 3 days in 200-ng/ml M-CSF and 400-ng/ml RANK-L (Peprotech, #315-11 and #315-02).
Bone histology
After dissection, whole femora were fixed in 4% paraformaldehyde (PFA) O/N at 4
• C. Next, samples were washed in 1×
phosphate-buffered saline (PBS) for 30 min and decalcified (if necessary) in 20% ethylenediaminetetraacetic acid (EDTA) for 4 weeks at 37
• C with weekly change of media. After decalcification, bones were rinsed in running water for 30 min and processed further for paraffin embedding. For histological staining, bones were embedded in paraffin blocks and sectioned into 5-μM thick sections using the microtome, then placed onto the surface of clean glass slides. Hematoxylin and eosin staining was performed by rehydration of sample sections and staining with hematoxylin for 2 min and eosin for 5 min. Slides were embedded with Eukitt for subsequent analysis.
Von Kossa/Alcian Blue staining was achieved by staining of femoral sections for 20 min with 1% silver nitrate under UV light and afterwards 20 min alcian blue (pH 2.2) at RT. Slides were embedded with Eukitt for subsequent analysis. DAB (3,3'-Diaminobenzidine) staining was performed using the ImmunoCruzTM ABC staining System according to the manufacturer's protocol (Santa Cruz, #sc-2018).
TRAP staining
TRAP staining of bone sections or primary osteoclast cultures was performed using the Acid Phosphatase, Leukocyte (TRAP) Kit 
Protein analysis
Proteins from cell cultures or tissues were isolated using RIPAbuffer containing cOmplete TM mini protease inhibitor cocktail (Sigma Aldrich, #11836153001) and protein concentration was measured using Bradford. Western blot analysis was performed as previously described (62) . The following antibodies were used for analysis: ACTB, 1:5000 (Sigma Aldrich, #A5316); CTSK, 1:1000 (Abcam, #ab19027); GAPDH, 1:1000 (Sigma Aldrich, #G9295); TRAP, 1:500 (Thermo Fisher Scientific, #436700); RELA, 1:1000 (Abcam, #ab16502); p-RELA, 1:1000 (Santa Cruz, # sc-136548); IKK alpha, 1:1000 (Abcam, #ab32041); IκBα, 1:1000 (Abcam, #ab7217); p-IκBα, 1:1000 (Invitrogen, #MA5-15224); Myc/DDK, 1:1000 (Origene, #TA50011); NFATC1, 1:500 (Abcam, #ab25916); PLS3, 1:1000 (15); V5, 1:3000 (Thermo Fisher Scientific, #R961-25); HRP-mouse, 1:5000 (Dianova, #115-035-146) and HRP-rabbit, 1:5000 (Cell Signaling, #7074). Protein levels were quantified by densitometric analysis using the 1Dscan EX program (Scanalytics, Rockville, MD, USA) normalized to a housekeeper.
Resorption Assay
Resorption assay was performed as previously described (63) . Briefly, osteoclasts were pre-differentiated in 10-cm petri dishes under the addition of 400-ng/ml M-CSF for 3 days and subsequent growth of cells for 3 days in 200-ng/ml M-CSF and 400-ng/ml RANK-L. Afterwards, cells were cultured on bovine bone slices (boneslices.com) for 7 days in M-CSF-and RANK-L-dosed medium. Cells were removed by ultrasonication and toluidine blue (Sigma Aldrich, #T3260) staining was performed to visualize resorption pits. Resorption pit area was quantified using Image J.
Immunohistochemistry
Osteoclasts were fixed with PFA and incubated with primary antibody (1:250) at 4
• C O/N. Incubation of the secondary antibody (1:500) was performed for 2 h at RT in the dark. DAB staining was performed using the ImmunoCruz TM ABC stain- 
Mass spectrometry
Identification of PLS3-binding partners was performed as earlier described (28) 
Co-IP
For Co-IP HEK293T cells were transfected with the human NKRF cDNA ORF clone containing a Myc-DDK-tag (OriGene, #RC208507). Extracted proteins were incubated in 35-μl anti-DDK microbeads for 2 h on ice to bind NKRF-DDK, which was used as bait to capture binding partners. Meanwhile, the μ-columns were permeabilized with a drop of 10% Triton-X 100 solution and washed 3× with 200-μl lysis buffer. Afterwards, the protein-microbead mix was added onto the prepared μ-column and washed 5× with 600-μl lysis buffer. To elute the proteins 60-μl 1× Laemmli buffer pre-heated to 95
• C were added to the μ-column. Next, protein levels of endogenous PLS3 were evaluated by western blotting. Input was used as control.
Quantitative reverse transcription PCR (qRT-PCR)
Total RNA was extracted from osteoclast cultures using the RNeasy Kit following the manufacturers protocol (Qiagen, #74104). Production of cDNA was performed using the QuantiTect Reverse Transcription Kit following the manufacturers protocol (Qiagen, #205310). Real-time PCR was performed using the Fast Start DNA Master SYBR green I kit (Roche, #03003230001). Specific primers and cycling conditions for each gene were used as previously described: Hprt was used as control (65) . Iκbα (65), Nfatc1 (66) and Rela (67) were analyzed.
ChIP
ChIP analysis was performed using osteoclast cultures from 2M-old male WT mice and the LowCell# ChIP Kit (Diagenode, #C01010072) according to the manufacturer's protocol. Briefly, protein-A magnetic beads were incubated with either the specific antibody (NKRF-IgG; Thermo Fisher Scientific, # PA5-41583) or control antibody (GFP-IgG ChIP Grade, Abcam, # ab290) for 2 h at 4 • C. Next, cells were harvested and fixed using 36.5% formaldehyde to cross-link proteins to DNA. Lysis of cells and chromatin shearing was performed using a Bioruptor ® , and immunoprecipitation was achieved using a magnetic rack. Finally, bound DNA was isolated and eluted and analyzed by quantitative PCR using the Power SYBR Green PCR Master Mix Kit (Thermo Fisher Scientific, #4368577) according to the manufacturer's protocol. A standard dilution series was prepared using 600-ng standard sample diluted in TE −4 and used for qRT-PCR with the following dilutions: 1:2.5, 1:5, 1:10, 1:20, 1:40, 1:80 and 1:160. qRT-PCR was performed using the StepOnePlus TM Real-Time PCR system (Applied Biosystems) and primers against Nfatc1 (66) and Ifnβ (68) at the same time with the same samples and executed using the Power SYBR Green PCR Master Mix Kit (Applied Biosystems). Results were obtained from four biological replicates processed in triplicates. Quantification was performed using the 'relative to control sequence' method (69) .
Statistical analysis
Statistical analyses were performed using Excel 2013 (Microsoft), SPSS Statistics 22 (IBM Corporation), GraphPad Prism 6 (Statcon) and SigmaPlot (Systat Software Inc.). Unpaired twotailed Student's t-test were used for equal and Mann-Whitney U test for unequal variances of two independent groups to compare the means. Holm-Bonferroni correction was applied for multiple comparisons. Statistical methods used to quantify data are stated in the figure legends. Sample size for each experiment was determined prior to execution through power analysis using G * Power 3.1 software. Data were considered to be significant at P ≥ 0.05 ( * P < 0.05, * * P < 0.01 and * * * P < 0.001). All data are presented as mean ± SEM.
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